Molecular structure alteration of IgG increased anticomplementary activity of intravenous immunoglobulin. 1995

X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
Department of Quality Control, Shanghai RAAS Blood Products Co Ltd, China.

OBJECTIVE To study the cause of anticomplementary activities (ACA) of intravenous immunoglobulins (IVIG). METHODS ACA were determined by two assays (limit test and 100CH50 test), distributions of IgG molecular size (polymer, dimer, monomer and fragment) by HPLC, IgG subclasses and IgA contents by radial immunodiffusion, prekallikrein activator (PKA) and kallikrein (KK) activities by chromogenic assay, potency of antibody against hepatitis B surface antigen (Anti-HBs) by enzyme-linked immunosorbent assay (ELISA). RESULTS The two ACA assays showed good correlation. However, ACA levels were not associated with distributions of IgG molecular size, IgG subclasses and IgA contents, PKA and KK activities. After heating incubation, ACA levels increased markedly and Anti-HBs decreased notably, distributions of IgG molecular size remained relatively constant. CONCLUSIONS Molecular structure alteration of IgG increased spontaneous complement activation of IVIG.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D011108 Polymers Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS). Polymer
D011288 Prekallikrein A plasma protein which is the precursor of kallikrein. Plasma that is deficient in prekallikrein has been found to be abnormal in thromboplastin formation, kinin generation, evolution of a permeability globulin, and plasmin formation. The absence of prekallikrein in plasma leads to Fletcher factor deficiency, a congenital disease. Fletcher Factor,Plasma Prokallikrein,Kallikreinogen,Plasma Prokallikrein A,Factor, Fletcher,Prokallikrein A, Plasma,Prokallikrein, Plasma
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003169 Complement Inactivator Proteins Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors. Complement Cytolysis Inhibiting Proteins,Complement Cytolysis Inhibitor Proteins,Complement Inactivating Proteins,Serum Complement Inactivators,Complement Inactivators, Serum,Inactivating Proteins, Complement,Inactivator Proteins, Complement,Inactivators, Serum Complement,Proteins, Complement Inactivating,Proteins, Complement Inactivator
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015941 Complement Hemolytic Activity Assay A screening assay for circulating COMPLEMENT PROTEINS. Diluted SERUM samples are added to antibody-coated ERYTHROCYTES and the percentage of cell lysis is measured. The values are expressed by the so called CH50, in HEMOLYTIC COMPLEMENT units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay. CH50 Assay,Complement H50,Hemolytic Titration Assay,Serum Complement Titer,Total Hemolytic Complement,Whole Complement Titer,CH(50),Assay, CH50,Assay, Hemolytic Titration,Assays, CH50,Assays, Hemolytic Titration,CH50 Assays,Complement H50s,Complement, Total Hemolytic,Complements, Total Hemolytic,Hemolytic Complement, Total,Hemolytic Complements, Total,Hemolytic Titration Assays,Serum Complement Titers,Titer, Serum Complement,Titer, Whole Complement,Titers, Serum Complement,Titers, Whole Complement,Titration Assay, Hemolytic,Titration Assays, Hemolytic,Total Hemolytic Complements,Whole Complement Titers
D016756 Immunoglobulins, Intravenous Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA. Antibodies, Intravenous,Human Intravenous Immunoglobulin,IV Immunoglobulin,IVIG,Intravenous Antibodies,Intravenous Immunoglobulin,Intravenous Immunoglobulins,Alphaglobin,Endobulin,Flebogamma DIF,Gamimmune,Gamimmune N,Gamimune,Gamimune N,Gammagard,Gammonativ,Gamunex,Globulin-N,IV Immunoglobulins,Immune Globulin Intravenous (Human),Immune Globulin, Intravenous,Immunoglobulins, Intravenous, Human,Intraglobin,Intraglobin F,Intravenous IG,Intravenous Immunoglobulins, Human,Iveegam,Modified Immune Globulin (Anti-Echovirus Antibody),Privigen,Sandoglobulin,Venimmune,Venoglobulin,Venoglobulin-I,Globulin N,Human Intravenous Immunoglobulins,Immunoglobulin, Human Intravenous,Immunoglobulin, IV,Immunoglobulin, Intravenous,Immunoglobulins, Human Intravenous,Immunoglobulins, IV,Intravenous Immune Globulin,Intravenous Immunoglobulin, Human,Venoglobulin I

Related Publications

X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
January 1989, Clinical therapeutics,
X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
March 1997, Biologicals : journal of the International Association of Biological Standardization,
X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
January 1975, Vox sanguinis,
X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
July 1969, Bulletin de la Societe de chimie biologique,
X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
April 1970, Vox sanguinis,
X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
November 1992, Ugeskrift for laeger,
X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
January 1993, Medycyna doswiadczalna i mikrobiologia,
X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
March 2014, The American journal of tropical medicine and hygiene,
X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
June 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
X X Zang, and Y Sun, and F Shen, and D Wang, and L Zhou, and J Wang, and E Kung
November 1988, The Journal of infection,
Copied contents to your clipboard!